Podcast 1001: Acute Intermediate Risk Pulmonary Embolism
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Contributor: Aaron Lessen, MD
Educational Pearls:
- Patients with pulmonary embolism (PE) are divided into three risk categories
- Low risk (non-massive PE): patients are stable
- Treatment: prescribe anticoagulants and discharge home
- Intermediate risk (submassive PE): patients are stable but display evidence of clot burden such as elevated troponin, elevated BNP, and/or right heart strain
- Treatment is controversial
- High risk (massive PE): patients are unstable with hypotension, hypoxia, and/or respiratory distress
- Treatment: IV thrombolysis to prevent decompensation
- Low risk (non-massive PE): patients are stable
- A recent randomized controlled trial evaluated treatment of intermediate risk PE patients
- Patients were randomized to receive either thrombectomy with anticoagulation or anticoagulation alone
- The primary outcome evaluated changes in right ventricular enlargement at 48 hours
- A controversial primary outcome because it does not speak to mortality or incidence of other necessary aggressive interventions
- Low clinical significance
- The study found that thrombectomy significantly reduced right ventricular enlargement faster than anticoagulation alone. However, there was no statistical difference in mortality or need for other treatments
- Treatment for intermediate risk PE patient remains controversial
- The same study will have second follow-up at 90 days to see if there are other benefits
References
- Lookstein RA, Konstantinides SV, Weinberg I, Dohad SY, Rosol Z, Kopeć G, Moriarty JM, Parikh SA, Holden A, Channick RN, McDonald B, Nagarsheth KH, Yamada K, Rosovsky RP; STORM-PE Trial Investigators. Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE Trial. Circulation. 2026 Jan 6;153(1):21-34. doi: 10.1161/CIRCULATIONAHA.125.077232. Epub 2025 Nov 3. PMID: 41183181.
Summarized by Meg Joyce, MS2 | Edited by Meg Joyce & Jorge Chalit, OMS4
Donate: https://emergencymedicalminute.org/donate/
Pas encore de commentaire